Moreover, the 36-month beta value for PRCT is 1.05. Analysts have varying opinions on the stock, with 6 analysts rating it as a “buy,” 2 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for PRCT is 51.55M and currently, short sellers hold a 11.99% of that float. On January 09, 2025, PRCT’s average trading volume was 794.74K shares.
PRCT) stock’s latest price update
The stock of Procept BioRobotics Corp (NASDAQ: PRCT) has decreased by -1.23 when compared to last closing price of 87.54. Despite this, the company has experienced a 7.38% gain in its stock price over the last five trading sessions. https://thefly.com reported 2024-12-03 that Wells Fargo resumed coverage of Procept BioRobotics with an Overweight rating and $112 price target. The firm believes aquablation remains early stages in its adoption, which will be further supported by a new product cycle, the analyst tells investors in a research note. Procept is comfortable with 2025 consensus estimates, Wells says, adding that the firm is receiving “generally positive” physician feedback on Hydros.
PRCT’s Market Performance
Procept BioRobotics Corp (PRCT) has experienced a 7.38% rise in stock performance for the past week, with a -8.84% drop in the past month, and a 16.84% rise in the past quarter. The volatility ratio for the week is 4.02%, and the volatility levels for the past 30 days are at 4.16% for PRCT. The simple moving average for the last 20 days is 1.43% for PRCT stock, with a simple moving average of 20.22% for the last 200 days.
Analysts’ Opinion of PRCT
Many brokerage firms have already submitted their reports for PRCT stocks, with Morgan Stanley repeating the rating for PRCT by listing it as a “Overweight.” The predicted price for PRCT in the upcoming period, according to Morgan Stanley is $105 based on the research report published on December 02, 2024 of the previous year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see PRCT reach a price target of $95. The rating they have provided for PRCT stocks is “Hold” according to the report published on November 14th, 2024.
Piper Sandler gave a rating of “Overweight” to PRCT, setting the target price at $42 in the report published on August 11th of the previous year.
PRCT Trading at -4.83% from the 50-Day Moving Average
After a stumble in the market that brought PRCT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -16.71% of loss for the given period.
Volatility was left at 4.16%, however, over the last 30 days, the volatility rate increased by 4.02%, as shares sank -6.55% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +25.72% upper at present.
During the last 5 trading sessions, PRCT rose by +7.38%, which changed the moving average for the period of 200-days by +81.37% in comparison to the 20-day moving average, which settled at $85.24. In addition, Procept BioRobotics Corp saw 7.38% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PRCT starting from Zadno Reza, who sale 26,423 shares at the price of $97.22 back on Dec 04 ’24. After this action, Zadno Reza now owns 152,762 shares of Procept BioRobotics Corp, valued at $2,568,844 using the latest closing price.
Nouri Alaleh, the EVP, CLO, CORP. SEC. of Procept BioRobotics Corp, sale 28,092 shares at $97.13 during a trade that took place back on Dec 04 ’24, which means that Nouri Alaleh is holding 52,472 shares at $2,728,574 based on the most recent closing price.
Stock Fundamentals for PRCT
Current profitability levels for the company are sitting at:
- -0.53 for the present operating margin
- 0.56 for the gross margin
The net margin for Procept BioRobotics Corp stands at -0.5. The total capital return value is set at -0.33. Equity return is now at value -37.02, with -25.16 for asset returns.
Based on Procept BioRobotics Corp (PRCT), the company’s capital structure generated 0.18 points at debt to capital in total, while cash flow to debt ratio is standing at -1.78. The debt to equity ratio resting at 0.21. The interest coverage ratio of the stock is -24.53.
Currently, EBITDA for the company is -98.09 million with net debt to EBITDA at 1.28. When we switch over and look at the enterprise to sales, we see a ratio of 22.95. The receivables turnover for the company is 2.89for trailing twelve months and the total asset turnover is 0.53. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.02.
Conclusion
To wrap up, the performance of Procept BioRobotics Corp (PRCT) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
